Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients

Critical Care Medicine

Volumn 30, Issue 8, 2002, Pages 1808-1814

  Hadley, Susan ^a   Lee, Winnie W ^a   Ruthazer, Robin ^a   Nasraway Jr , Stanley A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candidemia; Fungemia; Multiple organ failure; Outcomes; Sepsis; Septic shock

Indexed keywords

PLACEBO;

ADULT; ANAMNESIS; ARTICLE; BACTEREMIA; CANADA; CANDIDIASIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEART HEMODYNAMICS; HEMODYNAMIC MONITORING; HUMAN; IMMUNE SYSTEM; INTENSIVE CARE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; UNITED STATES;

EID: 0036345586     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200208000-00023     Document Type: Article

References (41)

1. National Nosocomial Infections Surveillance System: Secular trends in the epidemiology of nosocomial fungal infections in the United States
2. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
3. Epidemiology of nosocomial fungal infections, with emphasis on Candida species
4. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study
5. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
6. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
7. National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units
8. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
9. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
10. Hospital-acquired candidemia: The attributable mortality and excess length of stay
11. Candida infections in critically ill trauma patients: A retrospective case-control study
12. Septic shock: An analysis of outcomes for patients with onset on hospital wards versus intensive care units
13. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness
14. Predictors of adverse outcome in cancer patients with candidemia
15. Candida sepsis in surgical patients
16. Microbiological factors influencing the outcome of nosocomial bloodstream infections: A 6-year validated, population-based model
17. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults
18. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
19. A controlled clinical trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock
20. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units
21. Clinical Gram-positive sepsis: Does it fundamentally differ from Gram-negative bacterial sepsis?
22. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
23. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
24. Sepsis research: We must change course
25. Efficacy and safety of recombinant human activated protein C for severe sepsis
26. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
27. The systemic septic response: Does the organism matter?
28. APACHE II: A severity of disease classification system
29. Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit
30. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
31. Effects of fluconazole administration in critically ill patients: Analysis of bacterial and fungal resistance
32. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units
33. The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit
34. Fluconazole prophylaxis of severe Candida infection in trauma and post-surgical patients: A prospective, double-blind, placebo-controlled trial
35. Fluconazole prevents severe Candida spp infections in high-risk critically ill patients. A randomized, double-blind, placebo-controlled study
36. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients
37. Prophylactic fluconazole in liver transplant recipients
38. Risk factors for nosocomial candidemia: A case-control study in adults without leukemia
39. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
40. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome
41. Nosocomial candidemia: Risk factors and attributable mortality